North Liberty-based Steel Therapeutics, an early stage pharmarceutical company focused on increasing access to compounded drug therapies, announced Sept. 12 it has completed pre-investigational New Drug Application (pre-IND) communications with the U.S. Food and Drug Administration for its first product…